Kieburtz, Karl

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,668

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,224

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 716

Rate of functional decline in Huntington’s disease

Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology

Genetic Neurodegenerative DiseasesDeep Brain Stimulation and Movement Disorders

Cited by 362

The first frontier: digital biomarkers for neurodegenerative disorders

Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K. (2017) · Digital Biomarkers

Dementia and Cognitive Impairment ResearchMental Health Research Topics

Cited by 162

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A., Lee, D., Chang, J., Dubow, J., Dhall, R., et al. (2024) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 153

Novel Methods and Technologies for 21st-Century Clinical Trials: A Review

Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A., & Kieburtz, K. (2015) · JAMA Neurology

Statistical Methods in Clinical TrialsEthics in Clinical Research

Cited by 118

Parkinson’s progression markers initiative: a milestone-based strategy to monitor Parkinson’s disease progression

Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., et al. (2023) · Journal of Parkinson’s Disease

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 70

Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., et al. (2022) · Nature Medicine

Genetic Neurodegenerative DiseasesParkinson's Disease Mechanisms and Treatments

Cited by 67

Results of the citalopram to enhance cognition in Huntington disease trial

Beglinger, L. J., Adams, W. H., Langbehn, D., Fiedorowicz, J. G., Jorge, R., Biglan, K., Caviness, J., Olson, B., Robinson, R. G., Kieburtz, K., et al. (2014) · Movement Disorders

Genetic Neurodegenerative DiseasesParkinson's Disease Mechanisms and Treatments

Cited by 65

Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial

McGarry, A., McDermott, M. P., Kieburtz, K., Fung, W. L. A., McCusker, E., Peng, J., de Blieck, E. A., Cudkowicz, M., & for the Huntington Study Group 2CARE Investigators and Coordinators (2019) · Neurology

Genetic Neurodegenerative DiseasesSuicide and Self-Harm Studies

Cited by 24